Another therapeutic approach is the use of anti-CCR4 antibodies or CCR4 antagonists (receptor for CCL17/TARC and CCL22/MDC) in cancer therapy [257,258,259] to reduce the accumulation of Treg and thus enhance the immunotherapy and anticancer response of the immune system. Here, CCL17 is linked to cancer.